The National Institute for Health and Care Excellence and Flatiron Health are exploring how real-world evidence can inform the clinical and cost effectiveness of health technologies.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
